Brian Webster to sell Kestra (NASDAQ: KMTS) shares in Rule 144 trade

Rhea-AI Filing Summary

Kestra Medical Technologies shareholder Brian Webster has filed a Form 144 notice to sell 15,000 common shares. The proposed sale is through Merrill Lynch on NASDAQ, with an aggregate market value of $384,020.06, and an approximate sale date of February 17, 2026.

The 15,000 shares were acquired on March 7, 2025 via a restricted share issuance granted under the issuer’s equity compensation plan. Over the past three months, Webster sold 15,000 common shares on December 29, 2025 for $398,847.04 and another 15,000 shares on January 15, 2026 for $342,023.69.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Shares	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	15000	384020.06	58349053	02/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	03/07/2025	Restricted share issuance	KESTRA MEDICAL TECHNOLOGIES, LTD.			15000	03/07/2025	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brian Webster 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Shares	12/29/2025	15000	398847.04
Brian Webster 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Shares	01/15/2026	15000	342023.69

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Kestra Medical Technologies (KMTS) Form 144 filing show?

The Form 144 shows shareholder Brian Webster’s intent to sell 15,000 Kestra common shares. The planned transaction has an aggregate market value of $384,020.06 and is expected to occur on or around February 17, 2026 through Merrill Lynch on NASDAQ.

How many Kestra (KMTS) shares is Brian Webster planning to sell?

Brian Webster plans to sell 15,000 common shares of Kestra Medical Technologies. The filing lists an aggregate market value of $384,020.06, with the sale to be executed through Merrill Lynch on NASDAQ around February 17, 2026, subject to market conditions.

How did Brian Webster acquire the Kestra (KMTS) shares he plans to sell?

The 15,000 Kestra common shares were acquired on March 7, 2025 via a restricted share issuance. The filing states they were granted as part of the issuer’s equity compensation plan, rather than purchased for cash in an open-market transaction.

What Kestra (KMTS) share sales has Brian Webster made in the past three months?

Over the past three months, Brian Webster sold 15,000 common shares on December 29, 2025 for $398,847.04, and another 15,000 common shares on January 15, 2026 for $342,023.69, according to the Form 144 disclosure.

Which broker and exchange are involved in the new Kestra (KMTS) share sale?

The planned sale of 15,000 Kestra common shares will be handled by Merrill Lynch, listed at 225 Liberty Street, New York. The Form 144 indicates that the shares are expected to be sold on the NASDAQ stock market, subject to normal trading execution.

What does Rule 144 mean for the planned Kestra (KMTS) share sale?

Rule 144 allows limited public resale of restricted or control securities if certain conditions are met. The filing records Webster’s intent to sell 15,000 restricted shares, including acquisition details and recent sales history, to comply with Rule 144 disclosure requirements.